Wall Street Zen Downgrades Femasys (NASDAQ:FEMY) to Strong Sell

Femasys (NASDAQ:FEMY) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday, Wall Street Zen reports.

FEMY has been the subject of several other reports. Weiss Ratings downgraded shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Lake Street Capital dropped their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, August 18th. Finally, Maxim Group cut their price target on Femasys to $10.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Femasys currently has a consensus rating of “Moderate Buy” and an average price target of $50.00.

Femasys Stock Performance

FEMY opened at $2.05 on Friday. Femasys has a twelve month low of $1.96 and a twelve month high of $22.20. The company has a fifty day moving average of $2.69 and a 200-day moving average of $5.29. The stock has a market cap of $17.18 million, a PE ratio of -0.58 and a beta of -2.16. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Friday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.02). Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%. The business had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.73 million.

Insider Buying and Selling

In other Femasys news, CFO Dov Elefant purchased 15,625 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the chief financial officer owned 15,625 shares of the company’s stock, valued at $50,000. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of the business’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the transaction, the chief executive officer owned 15,625 shares of the company’s stock, valued at approximately $50,000. The trade was a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 38,750 shares of company stock valued at $124,000 over the last ninety days. 7.75% of the stock is currently owned by company insiders.

Femasys Company Profile

Femasys Inc is a women’s health company focused on developing and commercializing minimally invasive technologies for reproductive health and fertility care. The company’s products are designed to provide non-surgical or less invasive alternatives for contraception, diagnostic procedures and treatments involving the female reproductive system.

Femasys’ lead product candidate is FemBloc, an investigational, non-surgical permanent birth-control system intended to prevent pregnancy by blocking the fallopian tubes.